Eli Lilly (NYSE: LLY) is emerging as arguably the top stock in the anti-obesity market. It has a couple of fantastic products in Zepbound, which is approved for weight loss, and Mounjaro, which is essentially the same thing but is approved to treat diabetes. Between the two of them, the company is sitting on a gold mine, with their combined peak annual revenue potentially topping more than $50 billion. That's not too bad for a company that generated less than $35 billion in all of last year.

But as promising as those products may be, they aren't why I think Eli Lilly can hit a $1 trillion market capitalization and keep going higher. Instead, it's management's outlook for the future and its long-term strategy that should have investors bullish on the road ahead. This can still be an excellent stock to buy, even at what may seem like a hugely inflated valuation.

Being the top company in the anti-obesity market and the most valuable healthcare company in the world is impressive, but staying in those positions is going to be difficult, and Eli Lilly knows that. This is why management isn't content with sitting back and watching revenue for Zepbound and Mounjaro roll in. Instead, the company remains focused on building out its business so that it's even more robust, and so that it develops further products to fuel its long-term growth.

Continue reading

Source Fool.com